Roche Holding AG (RHHVF)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Roche Holding AG, with a price target of CHF425.00. The company’s shares closed last Wednesday at $389.20.
According to TipRanks.com, Papadakis is a 3-star analyst with an average return of
Currently, the analyst consensus on Roche Holding AG is a Moderate Buy with an average price target of $435.00, representing a 10.4% upside. In a report released yesterday, Bernstein also maintained a Buy rating on the stock with a CHF430.00 price target.
Akebia Therapeutics (AKBA)
H.C. Wainwright analyst Ed Arce downgraded Akebia Therapeutics to Hold today and set a price target of $2.00. The company’s shares closed last Wednesday at $0.83, close to its 52-week low of $0.67.
According to TipRanks.com, Arce is a 4-star analyst with an average return of
Currently, the analyst consensus on Akebia Therapeutics is a Hold with an average price target of $3.80, implying a 62.7% upside from current levels. In a report released yesterday, Piper Sandler also downgraded the stock to Hold with a $2.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RHHVF:
- Needham Thinks UiPath’s Stock is Going to Recover
- Micron is Processing Strong Revenues, Can it Continue?
- DocGo (DCGO) Gets a Buy Rating from Needham
- Mercedes-Benz Group (DDAIF) Received its Third Buy in a Row
- Analysts Are Bullish on These Healthcare Stocks: Siemens Healthineers AG (SEMHF), Clarus Therapeutics Holdings (CRXT)